DiaSorin SpA - Company Profile
Powered by 
All the sales intelligence you need on DiaSorin SpA in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how DiaSorin SpA fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with DiaSorin SpA.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
DiaSorin SpA (DiaSorin) is a medical diagnostics company that is engaged in the development, manufacturing, and marketing of in vitro diagnostics reagent kits and systems. The company specializes in the development, production, and marketing of reagent kits used by diagnostic laboratories worldwide. DiaSorin's major products include automated diagnostic analyzer platforms and specialized testing kits across immunodiagnostics, molecular diagnostics, and life sciences, including the LIAISON, VERIGENE, and xMAP technology systems designed for clinical laboratories and biomedical research. The company’s immunodiagnostic and molecular diagnostics products find application in the diagnosis of infectious diseases, endocrinology, gastrointestinal infections, autoimmunity, hypertension, emergency/ sepsis, bone metabolism, and oncology, among others. DiaSorin markets its products through direct sales forces and distributors. It has operations in North America, South America, South Africa, Europe, the Middle East, Africa, and Asia. DiaSorin is headquartered in Saluggia, Piedmont, Italy.
Headquarters
Italy
Address
Via Crescentino Snc, Saluggia, Piemonte, 13040
Website
int.diasorin.com
Telephone
39 016 1487526
No of Employees
3,272
Industry
Medical Equipment
Ticker Symbol & Exchange
DIA (BIT)
Revenue (2024)
$1.3B
0.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-17.3%
(2024 vs 2023)
Market Cap*
$4.3B
Net Profit Margin (2024)
XYZ
-18.0%
(2024 vs 2023)
* As of and is in US$
DiaSorin SpA premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Molecular Diagnostics and Point-of-Care Platforms: | Maintenance and Technical Support Services | LIAISON |
| 4-plex Respiratory Panel / Respiratory Flu Panel | On-Site Field Engineering | Simplexa |
| Respiratory Flex Assay | xMAP | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In March, the company signed a strategic distribution agreement with McKesson Medical Surgical to promote and support the commercialization of the LIAISON NES molecular point-of-care solution across physician offices, urgent care centers, and other decentralized testing locations in the US. |
| 2026 | New Products/Services | In February, the company, in partnership with QIAGEN, launched the LIAISON QuantiFERON-TB Gold Plus II Assay, a next-generation automated Interferon Gamma Release Assay (IGRA) for the US market. |
| 2026 | Contracts/Agreements | In January, the company entered into a distribution agreement with Fisher Scientific for the LIAISON NES molecular point-of-care (POC) platform in the U.S. hospital market. |
Competitor Comparison
| Key Parameters | DiaSorin SpA | Thermo Fisher Scientific Inc | Siemens Healthineers AG | Danaher Corp | Becton Dickinson and Co |
|---|---|---|---|---|---|
| Headquarters | Italy | United States of America | Germany | United States of America | United States of America |
| City | Saluggia | Waltham | Forchheim | Washington | Franklin Lakes |
| State/Province | Piemonte | Massachusetts | Bayern | WashingtonD.C. | New Jersey |
| No. of Employees | 3,272 | 125,000 | 72,000 | 58,000 | 72,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michele Denegri | Chairman | Executive Board | 2022 | 57 |
| Carlo Rosa | General Manager; Chief Executive Officer; Director | Executive Board | 2022 | 60 |
| Chen Menachem Even, PhD | Director; Chief Commercial Officer | Executive Board | 2022 | 63 |
| Alberto Donati | Chief Financial Officer | Senior Management | 2026 | 43 |
| Fabrizio Bonelli | Chief Scientific Officer | Senior Management | 2019 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer